*Corresponding author:Kenneth Bachmann, Ph.D., F.C.P. Vice President of Pharmacoinformatics and Cofounder, CeutiCare Co., Inc, Distinguished University Professor of Pharmacology, The University of Toledo, 7619 Olympic Parkway Sylvania, OH 43560, USA
Received: July 03, 2017; Published: July 07, 2017
To view the Full Article Peer-reviewed Article PDF
A 68 year male patient (KB) presented in August 2014 with profound muscle weakness of the hip and legs. Treatment with an 8 cycle regimen of CHOP for NHL 10 years earlier led to complete remission. He had also been treated for BPH with doxazosin, finasteride, and tadalafil. He was otherwise in good health with an eGFR of 77 mL/min. Rosuvastain had maintained lipid levels below targeted values for two years. He was subsequently referred to a neurologist (PZ). Radiological, laboratory, and neuromuscular tests were negative. KB abstained from rosuvastatin beginning in March, 2015. Subjective feelings and objective measures of muscle weakness began improving. Pravastatin 20mg challenge exacerbated weakness, and was stopped. Weakness improved until atorvastatin was initiated in October 2015, but was discontinued after only two doses when leg weakness worsened. The patient has been statin-free since November, 2015. On follow-up on February 10, 2016 muscle strength was objectively normal.
Keywords: Statins; Myelopathy; Myalgia; Myasthenia; Myositis
Abbreviations: MG: Myasthenia Gravis